LINC00517: A Non-Coding RNA Molecule as A Potential Drug Target

Target Name: LINC00517

NCBI ID: G400208

LINC00517

Other Name(s): C14orf26 | long intergenic non-protein coding RNA 517 | Long intergenic non-protein coding RNA 517

LINC00517: A Non-Coding RNA Molecule as A Potential Drug Target

LINC00517 is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. The molecule is derived from the gene C14orf26, which encodes a protein known as c-Myc.

C-Myc is a transcription factor that plays a crucial role in the development and maintenance of cancer. It has been shown to promote the growth and survival of cancer cells, and is often overexpressed in many types of cancer. LINC00517 is thought to work by binding to C-Myc and inhibiting its activity, which could lead to the suppression of cancer cell growth and the potential for the development of cancer.

The search for potential drug targets is an ongoing process in the field of cancer research, and LINC00517 is just one of the many potential targets that has been identified. The identification of a potential drug target is the first step in the process of developing a new drug treatment, and a significant discovery.

LINC00517 has been shown to be expressed in a variety of tissues and cells, including cancer cells, normal cells, and immune cells. It has also been shown to interact with several other molecules, including the protein PD-L1. PD-L1 is a protein that is expressed in many types of cancer, and has been shown to contribute to the development and progression of cancer. LINC00517 has been shown to interact with PD-L1, which could potentially make it a useful drug target for cancer treatment.

In addition to its potential as a drug target, LINC00517 has also been shown to have several potential biological functions. For example, it has been shown to regulate the expression of genes involved in cell adhesion, migration, and invasion. It has also been shown to play a role in the regulation of cell death, and has been shown to interact with the protein Bcl-2. Bcl-2 is a protein that has been shown to contribute to the survival of cancer cells, and LINC00517 has been shown to interact with it.

The potential uses of LINC00517 as a drug target are vast and varied. In addition to its potential as a cancer treatment, it may also be used to treat other diseases and disorders. For example, it has been shown to have potential in treating skin diseases, such as melanoma and non-melanoma skin cancers. It may also be used to treat respiratory diseases, such as chronic obstructive pulmonary disease (COPD).

In conclusion, LINC00517 is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. Its potential as a drug target is based on its ability to bind to C-Myc and inhibit its activity, as well as its potential biological functions, such as regulating cell adhesion, migration, and invasion, and regulating cell death. Further research is needed to determine the full potential of LINC00517 as a drug target, and to develop safe and effective treatments for cancer and other diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 517

The "LINC00517 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00517 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets